DYN Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) is expected to report earnings on October 28, 2026, after the market close. The consensus earnings estimate is a loss of $0.80 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.9% since its last earnings release on July 29, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Dyne Therapeutics, Inc.
Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases.
Sector
Healthcare
Industry
Biotechnology